Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Basilea Pharmaceutica's Net Margin % or its related term are showing as below:
FRA:PK5'
s Net Margin % Range Over the Past 10 Years
Min: -77.73 Med: -8.07 Max: 37.21
Current: 17.32
FRA:PK5's Net Margin % is ranked better than 85.55% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs FRA:PK5: 17.32
Basilea Pharmaceutica (FRA:PK5) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Basilea Pharmaceutica Net Margin % Related Terms
Basilea Pharmaceutica Net Margin % Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PK5 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Net Margin % distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (FRA:PK5) has a Net Margin % of 19.03% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #136 out of 941 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Basilea Pharmaceutica's Net Margin % too high?
Basilea Pharmaceutica's current Net Margin % is 19.03%. Based on the distribution chart, Basilea Pharmaceutica ranks #136 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #136 out of 941 companies for Net Margin %. This places Basilea Pharmaceutica in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Net Margin % is 19.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €62.49, compared to a current price of €59.30 — trading 5.1% below its estimated fair value. The current Net Margin % is 19.03%. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current Net Margin % is 19.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of €59.30 is trading 5.1% below its estimated GF Value™ of €62.49.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for FRA:PK5:
Net Margin %: 19.03%
GF Value™: €62.49 vs. price of €59.30 (5.1% below fair value)
No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for FRA:PK5
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PK5 has been successfully added to your 
